BTAI250117C4500
- 0.05
- 0.000.00%
BioXcel Therapeutics Newsroom
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5
BioXcel Therapeutics Analyst Ratings
Bioxcel Therapeutics: Strategic Initiatives and Market Opportunities Drive Buy Rating Amid Financial Challenges
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1
BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating
Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5
BioXcel Therapeutics Is Maintained at Buy by HC Wainwright & Co.
BioXcel Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $7 Price Target
BioXcel Therapeutics Analyst Ratings
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Bioxcel Therapeutics (BTAI) Receives a Hold From Mizuho Securities
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $7
BioXcel Therapeutics Analyst Ratings
Buy Rating Maintained for Bioxcel Therapeutics Amid Positive Performance and Growth Prospects
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target
BioXcel Therapeutics Analyst Ratings